Citius Pharmaceuticals (CTXR)
(Delayed Data from NSDQ)
$0.65 USD
-0.02 (-2.86%)
Updated May 17, 2024 04:00 PM ET
After-Market: $0.65 0.00 (0.25%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CTXR 0.65 -0.02(-2.86%)
Will CTXR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CTXR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTXR
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
CTXR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CTXR
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
Citius Pharmaceuticals Non-GAAP EPS of -$0.05
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences